1-3 of 3
Johannes Sam, PhD
Close
Sort by
Journal Articles

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter, PhD, Johannes Sam, PhD, Claudia Ferrara Koller, PhD, Sarah Diggelmann, Esther Bommer, Anne Schönle, Christina Claus, PhD, Marina Bacac, PhD, Christian Klein, PhD, Pablo Umana, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40.
https://doi.org/10.1182/blood-2020-134782
Published: 2020
Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Christian Klein, PhD, Christian Augsberger, Wei Xu, MD PhD, Christina Heitmüller, PhD, Lydia Hanisch, PhD, Johannes Sam, PhD, Vesna Pulko, PhD, Anne Schönle, John Challier, PhD, Alejandro Carpy, PhD, Nikola Konstandin, PhD, Maurine Rothe, Gerulf Hänel, Veit Bücklein, MD, Felix S. Lichtenegger, MD, Antje Tunger, PhD, Marc Schmitz, MD, Michael von Bergwelt, Karsten Spiekermann, MD, Pablo Umana, PhD, Marion Subklewe, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4450.
https://doi.org/10.1182/blood-2019-130121
Published: 2019
Journal Articles

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

Marina Bacac, PhD, Pablo Umaña, PhD, Sylvia Herter, PhD, Sara Colombetti, PhD, Johannes Sam, PhD, Marine Le Clech, Anne Freimoser-Grundschober, PhD, Marine Richard, Valeria Nicolini, PhD, Christian Gerdes, PhD, Laurent Lariviere, PhD, Christiane Neumann, PhD, Christian Klein, PhD
Journal: Blood
Blood (2016) 128 (22): 1836.
https://doi.org/10.1182/blood.V128.22.1836.1836
Published: 2016